Key facts
- Instylla’s last known valuation is $199.7M (Oct 2025).
- It has raised $85.3M across 5 recorded rounds; the latest was Early Stage VC ($21.7M) in Jul 2025.
- Notable investors include Ascension Ventures, Sparta Group, AMED Ventures, Angel Physicians Fund, Catalyst Health Ventures — 8 tracked in total.
- Instylla has filed 5 Form Ds with the SEC since 2017, most recently Nov 2023 ($30.3M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Instylla
Funding rounds
5 roundsAbout Instylla
Developer of a liquid embolic designed for interventional radiology. The company's offering is designed for controlled, complete, and persistent embolization and to deliver initial clinical applications in interventional oncology and peripheral hemostasis, enabling healthcare professionals to have access to novel embolization products to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Bedford, MA, United States
- Founded
- 2017
- Employees
- 49
- Website
- instylla.com/
- Ownership
- Privately Held (backing)
Instylla doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Instylla shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Instylla in its N-PORT filings yet. We sweep new filings monthly.